A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor
- Indications Acute coronary syndromes; Coronary artery disease; Stroke
- Focus Pharmacodynamics
- 11 Oct 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 11 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 12 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Feb 2017.